Abstract
Background: Male breast cancer is rare, accounting for approximately 0.5% - 1.0% of all breast cancer cases; hormone-dependent luminal type male breast cancer is the most common. The proportion of hormone receptor-negative and human epithelial growth factor Receptor type 2-positive breast cancer is extremely low among male breast cancer. A patient with advanced HER2 type breast cancer, a rare male breast cancer, was successfully treated with pertuzumab, trastuzumab, and eribulin therapy. Case Presentation: A 75- year-old man presented to our hospital with induration of the right anterior chest and lymphoedema of the right upper limb. Based on the results of core needle biopsy, he was diagnosed with HER2 type invasive ductal carcinoma associated with bone metastasis (stage IV). Chemotherapy with pertuzumab, trastuzumab, and eribulin was started. The drugs were remarkably effective, and his lymphoedema tended to improve. Conclusion: We reported a successful case of chemotherapy and targeted therapy for a rare male breast cancer of HER2 positive and hormone negative type.
Highlights
Male breast cancer is rare, accounting for approximately 0.5% 1.0% of all breast cancer cases; hormone-dependent luminal type male breast cancer is the most common
The proportion of hormone receptor-negative and human epithelial growth factor Receptor type 2-positive breast cancer is extremely low among male breast cancer
Based on the results of core needle biopsy, he was diagnosed with Human Epithelial growth factor Receptor type 2 (HER2) type invasive ductal carcinoma associated with bone metastasis
Summary
Male breast cancer (MBC) is rare, accounting for approximately 0.5% - 1.0% of all breast cancer cases; hormone-dependent luminal type MBC is the most common. The proportion of hormone receptor-negative and Human Epithelial growth factor Receptor type 2 (HER2)-positive breast cancer is extremely low among MBCs and accounts for 0.6% - 1.2% of MBCs; in such cases, the prognosis is often poor [1] [2] [3] [4]. After completing 3 cycles, CT showed reduction in lymph node swelling; a marked decrease was observed in tumor marker levels (CEA, 5.8 ng/mL and CA15-3, 57.5 U/mL) (Figure 3). He maintained partial response with chemotherapy, and no adverse reactions were observed.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
